{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T23:04:57Z","timestamp":1785020697510,"version":"3.55.0"},"reference-count":171,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2022,7,8]]},"abstract":"<jats:p>Multiple system atrophy is a rapidly progressive and fatal neurodegenerative disorder. While numerous preclinical studies suggested efficacy of potentially disease modifying agents, none of those were proven to be effective in large-scale clinical trials. Three major strategies are currently pursued in preclinical and clinical studies attempting to slow down disease progression. These target \u03b1-synuclein, neuroinflammation, and restoration of neurotrophic support. This review provides a comprehensive overview on ongoing preclinical and clinical developments of disease modifying therapies. Furthermore, we will focus on potential shortcomings of previous studies that can be avoided to improve data quality in future studies of this rare disease.<\/jats:p>","DOI":"10.3233\/jpd-223183","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T12:22:58Z","timestamp":1651234978000},"page":"1369-1387","source":"Crossref","is-referenced-by-count":21,"title":["Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?"],"prefix":"10.1177","volume":"12","author":[{"given":"Victoria","family":"Sidoroff","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Bower","sequence":"additional","affiliation":[{"name":"The Multiple System Atrophy Coalition, Inc., McLean, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Stefanova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fanciulli","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Stankovic","sequence":"additional","affiliation":[{"name":"Neurology Clinic, University Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Seppi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor K.","family":"Wenning","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krismer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-223183_ref1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJMra1311488","article-title":"Multiple-system atrophy","volume":"372","author":"Fanciulli","year":"2015","journal-title":"N Engl J Med"},{"key":"10.3233\/JPD-223183_ref2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.3233\/JPD-223183_ref3","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/brain\/awz189","article-title":"Improving diagnostic accuracy of multiple system atrophy: A clinicopathological study","volume":"142","author":"Miki","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JPD-223183_ref4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00401-012-0977-5","article-title":"Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human \u03b1-synuclein under oligodendrocyte promoter: Implications for multiple system atrophy","volume":"124","author":"Stefanova","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-223183_ref5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0002-9440(10)62307-3","article-title":"Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy","volume":"166","author":"Stefanova","year":"2005","journal-title":"Am J Pathol"},{"key":"10.3233\/JPD-223183_ref6","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00415-020-09781-9","article-title":"Diagnostic utility of fluid biomarkers in multiple system atrophy: A systematic review and meta-analysis","volume":"268","author":"Cong","year":"2021","journal-title":"J Neurol"},{"key":"10.3233\/JPD-223183_ref7","doi-asserted-by":"crossref","first-page":"a024588","DOI":"10.1101\/cshperspect.a024588","article-title":"\u03b1-synuclein: Multiple system atrophy prions","volume":"8","author":"Woerman","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.3233\/JPD-223183_ref8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3233\/JAD-170397","article-title":"Multiple system atrophy: An oligodendroglioneural synucleinopathy","volume":"62","author":"Jellinger","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JPD-223183_ref9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40478-019-0730-6","article-title":"Understanding the pathogenesis of multiple system atrophy: State of the art and future perspectives","volume":"7","author":"Monzio Compagnoni","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JPD-223183_ref10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/nan.12661","article-title":"Signs of early cellular dysfunction in multiple system atrophy","volume":"47","author":"Herrera-Vaquero","year":"2021","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JPD-223183_ref11","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/nan.12688","article-title":"MOBP and HIP1 in multiple system atrophy: New \u03b1-synuclein partners in glial cytoplasmic inclusions implicated in the disease pathogenesis","volume":"47","author":"Bettencourt","year":"2021","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JPD-223183_ref12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00441-018-2839-5","article-title":"\u03b1-Synuclein strains and seeding in Parkinson\u2019s disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: Similarities and differences","volume":"373","author":"Peelaerts","year":"2018","journal-title":"Cell Tissue Res"},{"key":"10.3233\/JPD-223183_ref13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fnmol.2019.00107","article-title":"Spreading of \u03b1-synuclein and tau: A systematic comparison of the mechanisms involved","volume":"12","author":"Vasili","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JPD-223183_ref14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40478-018-0532-2","article-title":"Potent prion-like behaviors of pathogenic \u03b1-synuclein and evaluation of inactivation methods","volume":"6","author":"Tarutani","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JPD-223183_ref15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41374-019-0198-9","article-title":"Dissecting \u03b1-synuclein inclusion pathology diversity in multiple system atrophy: Implications for the prion-like transmission hypothesis","volume":"99","author":"Dhillon","year":"2019","journal-title":"Lab Invest"},{"key":"10.3233\/JPD-223183_ref16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00441-018-2814-1","article-title":"The concept of alpha-synuclein as a prion-like protein: Ten years after","volume":"373","author":"Steiner","year":"2018","journal-title":"Cell Tissue Res"},{"key":"10.3233\/JPD-223183_ref17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41374-019-0195-z","article-title":"Transmission of \u03b1-synuclein seeds in neurodegenerative disease: Recent developments","volume":"99","author":"Karpowicz","year":"2019","journal-title":"Lab Invest"},{"key":"10.3233\/JPD-223183_ref18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/cells10020375","article-title":"Alpha-synuclein: Mechanisms of release and pathology progression in synucleinopathies","volume":"10","author":"Br\u00e1s","year":"2021","journal-title":"Cells"},{"key":"10.3233\/JPD-223183_ref19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/nan.12592","article-title":"Invited Review: The role of prion-like mechanisms in neurodegenerative diseases","volume":"46","author":"Jaunmuktane","year":"2020","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JPD-223183_ref20","doi-asserted-by":"crossref","first-page":"614587","DOI":"10.3389\/fnagi.2020.614587","article-title":"Absence of uptake and prion-like spreading of alpha-synuclein and tau after intravitreal injection of preformed fibrils","volume":"12","author":"Veys","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JPD-223183_ref21","doi-asserted-by":"crossref","first-page":"e1008222","DOI":"10.1371\/journal.ppat.1008222","article-title":"Kinetics of \u03b1-synuclein prions preceding neuropathological inclusions in multiple system atrophy","volume":"16","author":"Woerman","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.3233\/JPD-223183_ref22","doi-asserted-by":"crossref","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","article-title":"Evidence for \u03b1-synuclein prions causing multiple system atrophy in humans with parkinsonism","volume":"112","author":"Prusiner","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-223183_ref23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00401-019-01959-4","article-title":"Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines","volume":"137","author":"Woerman","year":"2019","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-223183_ref24","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1073\/pnas.1318268110","article-title":"Transmission of multiple system atrophy prions to transgenic mice","volume":"110","author":"Watts","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-223183_ref25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/nan.12299","article-title":"Review: Spreading the word: Precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein","volume":"42","author":"Rey","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JPD-223183_ref26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00401-019-02057-1","article-title":"Alpha-synuclein: Prion or prion-like?","volume":"138","author":"Leak","year":"2019","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-223183_ref27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00441-017-2712-y","article-title":"A critical review of the prion hypothesis of human synucleinopathies","volume":"373","author":"Tamg\u00fcney","year":"2018","journal-title":"Cell Tissue Res"},{"key":"10.3233\/JPD-223183_ref28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ana.25132","article-title":"Is multiple system atrophy an infectious disease?","volume":"83","author":"Wenning","year":"2018","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-223183_ref29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/v11030261","article-title":"Prion and prion-like protein strains: Deciphering the molecular basis of heterogeneity in neurodegeneration","volume":"11","author":"Scial\u00f2","year":"2019","journal-title":"Viruses"},{"key":"10.3233\/JPD-223183_ref30","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/mds.27894","article-title":"Multiple system atrophy: Recent developments and future perspectives","volume":"34","author":"Meissner","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tins.2016.10.008","article-title":"The threshold theory for Parkinson\u2019s disease","volume":"40","author":"Engelender","year":"2017","journal-title":"Trends Neurosci"},{"key":"10.3233\/JPD-223183_ref32","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson\u2019s disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.3233\/JPD-223183_ref33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: Mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-223183_ref34","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12035-021-02596-3","article-title":"An update on the critical role of \u03b1-synuclein in Parkinson\u2019s disease and other synucleinopathies: From tissue to cellular and molecular levels","volume":"59","author":"Serratos","year":"2022","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JPD-223183_ref35","doi-asserted-by":"crossref","first-page":"104587","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson\u2019s disease: Current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-223183_ref36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JPD-223183_ref37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: A randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-223183_ref38","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/mds.28218","article-title":"A phase 1 randomized trial of specific active \u03b1-synuclein immunotherapies PD01A and PD03A in multiple system atrophy","volume":"35","author":"Meissner","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref40","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: A randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-223183_ref42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-223183_ref43","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.3233\/JPD-223183_ref44","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J Neurosci"},{"key":"10.3233\/JPD-223183_ref45","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JPD-223183_ref47","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JPD-223183_ref48","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JPD-223183_ref49","doi-asserted-by":"crossref","first-page":"e135633","DOI":"10.1172\/jci.insight.135633","article-title":"\u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease","volume":"6","author":"Cole","year":"2021","journal-title":"JCI Insight"},{"key":"10.3233\/JPD-223183_ref50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson\u2019s disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.3233\/JPD-223183_ref51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2018.00036","article-title":"Silencing alpha synuclein in mature nigral neurons results in rapid neuroinflammation and subsequent toxicity","volume":"11","author":"Benskey","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JPD-223183_ref52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-3-19","article-title":"In vivo silencing of alpha-synuclein using naked siRNA","volume":"3","author":"Lewis","year":"2008","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JPD-223183_ref53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.nbd.2019.01.004","article-title":"Long-term RNAi knockdown of \u03b1-synuclein in the adult rat substantia nigra without neurodegeneration","volume":"125","author":"Zharikov","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-223183_ref54","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1471-4159.2008.05611.x","article-title":"Greentea extracts interfere with the stress-protective activity of PrP and the formation of PrP","volume":"107","author":"Rambold","year":"2008","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-223183_ref55","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.3233\/JPD-223183_ref56","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-223183_ref57","doi-asserted-by":"crossref","first-page":"21299","DOI":"10.1074\/jbc.M114.554667","article-title":"How epigallocatechin gallate can inhibit \u03b1-synuclein oligomer toxicity in vitro","volume":"289","author":"Lorenzen","year":"2014","journal-title":"J Biol Chem"},{"key":"10.3233\/JPD-223183_ref58","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.neuroscience.2014.12.003","article-title":"Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral \u03b1-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys","volume":"286","author":"Chen","year":"2015","journal-title":"Neuroscience"},{"key":"10.3233\/JPD-223183_ref59","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3945\/jn.117.255034","article-title":"Epigallocatechin gallate has a neurorescue effect in a mouse model of Parkinson disease","volume":"147","author":"Xu","year":"2017","journal-title":"J Nutr"},{"key":"10.3233\/JPD-223183_ref60","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1474-4422(19)30141-3","article-title":"Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): A randomised, double-blind, placebo-controlled trial","volume":"18","author":"Levin","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-223183_ref61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00702-016-1507-8","article-title":"The PROMESA-protocol: Progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach","volume":"123","author":"Levin","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JPD-223183_ref62","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/brain\/aww238","article-title":"A de novo compound targeting \u03b1-synuclein improves deficits in models of Parkinson\u2019s disease","volume":"139","author":"Wrasidlo","year":"2016","journal-title":"Brain"},{"key":"10.3233\/JPD-223183_ref63","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease","volume":"8","author":"Price","year":"2018","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-223183_ref64","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-223183_ref65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.27562","article-title":"Anle138b modulates \u03b1-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy","volume":"34","author":"Heras-Garvin","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40035-020-00217-y","article-title":"Targeting \u03b1-synuclein by PD03 AFFITOPE\u00ae and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: Clinical relevance","volume":"9","author":"Lemos","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.3233\/JPD-223183_ref68","doi-asserted-by":"crossref","first-page":"27660","DOI":"10.1074\/jbc.M115.686584","article-title":"Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of \u03b1-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL)","volume":"290","author":"Follmer","year":"2015","journal-title":"J Biol Chem"},{"key":"10.3233\/JPD-223183_ref69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","article-title":"The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson\u2019s disease","volume":"5","author":"Finkelstein","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"15 Suppl","key":"10.3233\/JPD-223183_ref70","first-page":"P5.8","article-title":"PBT434 prevents \u03b1-synuclein aggregation, neuron loss, motor dysfunction and reduces glial cell inclusions in a transgenic mouse model of multiple system atrophy","volume":"92","author":"Finkelstein","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JPD-223183_ref71","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1002\/mds.28714","article-title":"ATH434 reduces \u03b1-synuclein-related neurodegeneration in a murine model of multiple system atrophy","volume":"36","author":"Heras-Garvin","year":"2021","journal-title":"Mov Disord"},{"issue":"Suppl 15","key":"10.3233\/JPD-223183_ref72","doi-asserted-by":"crossref","first-page":"S4.001","DOI":"10.1212\/WNL.92.15_supplement.S4.001","article-title":"A first in human study of PBT434, a novel small molecule inhibitor of \u03b1-synuclein aggregation","volume":"92","author":"Stamler","year":"2019","journal-title":"Neurology"},{"issue":"15 Suppl","key":"10.3233\/JPD-223183_ref73","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1212\/WNL.94.15_supplement.4871","article-title":"A phase 1 study of PBT434, a novel small molecule inhibitor of \u03b1-synuclein aggregation, in adult and older adult volunteers","volume":"94","author":"Stamler","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JPD-223183_ref75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10286-019-00662-4","article-title":"Inhibition of the mammalian target or rapamycin (mTOR): A potential therapeutic strategy for multiple system atrophy","volume":"30","author":"Ndayisaba","year":"2020","journal-title":"Clin Auton Res"},{"key":"10.3233\/JPD-223183_ref76","first-page":"779","article-title":"The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human microglial cells","volume":"18","author":"Cappoli","year":"2019","journal-title":"EXCLI J"},{"key":"10.3233\/JPD-223183_ref77","unstructured":"Lopez-Cuina M , Guerin P , Bezard E , Meissner W , Fernagut P (2018) Rapamycin for treating MSA: A preclinical proof of concept study. Mov Disord 33(Suppl 2)https:\/\/www.mdsabstracts.org\/abstract\/rapamycin-for-treating-msa-a-preclinical-proof-of-concept-study\/."},{"key":"10.3233\/JPD-223183_ref78","doi-asserted-by":"crossref","first-page":"28743","DOI":"10.3402\/pba.v5.28743","article-title":"Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy","volume":"5","author":"Bai","year":"2015","journal-title":"Pathobiol Aging Age Relat Dis"},{"key":"10.3233\/JPD-223183_ref79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12868-018-0431-2","article-title":"Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived \u03b1-synuclein in oligodendroglia: Implications for MSA pathogenesis","volume":"19","author":"Fellner","year":"2018","journal-title":"BMC Neurosci"},{"key":"10.3233\/JPD-223183_ref80","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","article-title":"Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils","volume":"11","author":"Li","year":"2004","journal-title":"Chem Biol"},{"key":"10.3233\/JPD-223183_ref81","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/WNR.0b013e32830b3661","article-title":"Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy","volume":"19","author":"Ubhi","year":"2008","journal-title":"Neuroreport"},{"key":"10.3233\/JPD-223183_ref82","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","article-title":"Efficacy and safety of rifampicin for multiple system atrophy: A randomised, double-blind, placebo-controlled trial","volume":"13","author":"Low","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-223183_ref83","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JPD-223183_ref84","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4172\/2155-9899.1000259","article-title":"Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in \u03b1-synucleinopathy","volume":"5","author":"Hebron","year":"2014","journal-title":"J Clin Cell Immunol"},{"key":"10.3233\/JPD-223183_ref85","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease","volume":"4","author":"Karuppagounder","year":"2014","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-223183_ref86","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","article-title":"c-Abl phosphorylates \u03b1-synuclein and regulates its degradation: Implication for \u03b1-synuclein clearance and contribution to the pathogenesis of Parkinson\u2019s disease","volume":"23","author":"Mahul-Mellier","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JPD-223183_ref87","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/mds.28034","article-title":"Nilotinib fails to prevent synucleinopathy and cell loss in a mouse model of multiple system atrophy","volume":"35","author":"Lopez-Cuina","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref88","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-223183_ref89","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: A phase 2 randomized clinical trial","volume":"77","author":"Pagan","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-223183_ref90","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of nilotinib in patients with moderately advanced Parkinson disease: A randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-223183_ref91","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12868-015-0222-y","article-title":"Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement","volume":"16","author":"Hou","year":"2015","journal-title":"BMC Neurosci"},{"key":"10.3233\/JPD-223183_ref92","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/00207454.2012.729234","article-title":"Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: Possible mediation through enhanced autophagy","volume":"123","author":"Li","year":"2013","journal-title":"Int J Neurosci"},{"key":"10.3233\/JPD-223183_ref93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.parkreldis.2020.01.010","article-title":"MSA: From mechanisms to experimental therapeutics","volume":"73","author":"Heras-Garvin","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-223183_ref94","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00415-012-6655-7","article-title":"A randomized clinical trial of lithium in multiple system atrophy","volume":"260","author":"Sacc\u00e0","year":"2013","journal-title":"J Neurol"},{"key":"10.3233\/JPD-223183_ref95","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1039\/B915145C","article-title":"Molecular clips and tweezers hosting neutral guests","volume":"40","author":"Hardouin-Lerouge","year":"2011","journal-title":"Chem Soc Rev"},{"key":"10.3233\/JPD-223183_ref97","doi-asserted-by":"crossref","first-page":"165513","DOI":"10.1016\/j.bbadis.2019.07.007","article-title":"The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent \u03b1-synuclein in experimental multiple system atrophy","volume":"1865","author":"Herrera-Vaquero","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.3233\/JPD-223183_ref98","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.jmb.2014.04.015","article-title":"A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies","volume":"426","author":"Krishnan","year":"2014","journal-title":"J Mol Biol"},{"key":"10.3233\/JPD-223183_ref99","doi-asserted-by":"crossref","first-page":"10486","DOI":"10.1073\/pnas.1804198115","article-title":"Small molecule inhibits \u03b1-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.10481-","volume":"115","author":"Pujols","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-223183_ref101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/mt.2012.66","article-title":"Lentivirus mediated delivery of neurosin promotes clearance of wild-type \u03b1-synuclein and reduces the pathology in an \u03b1-synuclein model of LBD","volume":"21","author":"Spencer","year":"2013","journal-title":"Mol Ther"},{"key":"10.3233\/JPD-223183_ref102","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-015-0043-6","article-title":"A brain-targeted, modified neurosin (kallikrein-6) reduces \u03b1-synuclein accumulation in a mouse model of multiple system atrophy","volume":"10","author":"Spencer","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JPD-223183_ref103","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/nan.12512","article-title":"Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of \u03b1-synuclein in multiple system atrophy","volume":"45","author":"Kiely","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JPD-223183_ref104","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fncel.2015.00437","article-title":"Neuroinflammation in multiple system atrophy: Response to and cause of \u03b1-synuclein aggregation","volume":"9","author":"Vieira","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.3233\/JPD-223183_ref105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neuroscience.2015.02.008","article-title":"The relation between \u03b1-synuclein and microglia in Parkinson\u2019s disease: Recent developments","volume":"302","author":"Sanchez-Guajardo","year":"2015","journal-title":"Neuroscience"},{"key":"10.3233\/JPD-223183_ref106","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12640-011-9294-3","article-title":"Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model","volume":"21","author":"Stefanova","year":"2012","journal-title":"Neurotox Res"},{"key":"10.3233\/JPD-223183_ref107","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bpa.12371","article-title":"Neuroinflammation in synucleinopathies","volume":"26","author":"Lim","year":"2016","journal-title":"Brain Pathol"},{"key":"10.3233\/JPD-223183_ref108","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.28814","article-title":"Glia imaging differentiates multiple system atrophy from Parkinson\u2019s disease: A positron emission tomography study with [11 C]PBR28 and machine learning analysis","volume":"37","author":"Jucaite","year":"2022","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-017-0863-0","article-title":"Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine\/chemokine profiles: A case control study","volume":"14","author":"Yamasaki","year":"2017","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JPD-223183_ref110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/glia.20051","article-title":"Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus","volume":"48","author":"Ryu","year":"2004","journal-title":"Glia"},{"key":"10.3233\/JPD-223183_ref111","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mds.22732","article-title":"Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial)","volume":"25","author":"Dodel","year":"2010","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jnen\/63.1.43","article-title":"Microglial activation parallels system degeneration in multiple system atrophy","volume":"63","author":"Ishizawa","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JPD-223183_ref113","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/mds.21259","article-title":"Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients","volume":"22","author":"Langerveld","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref114","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2377-12-131","article-title":"Treatment of multiple system atrophy using intravenous immunoglobulin","volume":"12","author":"Novak","year":"2012","journal-title":"BMC Neurol"},{"key":"10.3233\/JPD-223183_ref115","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1523\/JNEUROSCI.0970-05.2005","article-title":"Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson\u2019s disease in mice","volume":"25","author":"Choi","year":"2005","journal-title":"J Neurosci"},{"key":"10.3233\/JPD-223183_ref116","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1471-4159.2004.02527.x","article-title":"Neuronal expression of myeloperoxidase is increased in Alzheimer\u2019s disease","volume":"90","author":"Green","year":"2004","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-223183_ref117","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1750-3639.2007.00110.x","article-title":"Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis","volume":"18","author":"Gray","year":"2008","journal-title":"Brain Pathol"},{"key":"10.3233\/JPD-223183_ref118","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12640-015-9547-7","article-title":"Failure of neuroprotection despite microglial suppression by delayed-start myeloperoxidase inhibition in a model of advanced multiple system atrophy: Clinical implications","volume":"28","author":"Kaindlstorfer","year":"2015","journal-title":"Neurotox Res"},{"key":"10.3233\/JPD-223183_ref119","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awv184","article-title":"Effect of the myeloperoxidase inhibitor AZD3241 on microglia: A PET study in Parkinson\u2019s disease","volume":"138","author":"Jucaite","year":"2015","journal-title":"Brain"},{"key":"10.3233\/JPD-223183_ref121","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1073\/pnas.1610099113","article-title":"Caspase-1 causes truncation and aggregation of the Parkinson\u2019s disease-associated protein \u03b1-synuclein","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-223183_ref122","doi-asserted-by":"crossref","first-page":"9593","DOI":"10.1073\/pnas.1609291113","article-title":"Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy","volume":"113","author":"Bassil","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-223183_ref123","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40478-016-0409-1","article-title":"Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy","volume":"5","author":"Valera","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JPD-223183_ref124","doi-asserted-by":"crossref","first-page":"107701","DOI":"10.1016\/j.neuropharm.2019.107701","article-title":"FTY720-Mitoxy reduces toxicity associated with MSA-like \u03b1-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures","volume":"158","author":"Vargas-Medrano","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-223183_ref125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neuropharm.2017.01.028","article-title":"FTY720 (Fingolimod) reverses \u03b1-synuclein-induced downregulation of brain-derived neurotrophic factor mRNA in OLN-93 oligodendroglial cells","volume":"117","author":"Segura-Ulate","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-223183_ref126","doi-asserted-by":"crossref","first-page":"113120","DOI":"10.1016\/j.expneurol.2019.113120","article-title":"FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in multiple system atrophy mouse models","volume":"325","author":"Vidal-Martinez","year":"2020","journal-title":"Exp Neurol"},{"key":"10.3233\/JPD-223183_ref127","doi-asserted-by":"crossref","first-page":"107919","DOI":"10.1016\/j.neuropharm.2019.107919","article-title":"Anti-neuroinflammatory, protective effects of the synthetic microneurotrophin BNN-20 in the advanced dopaminergic neurodegeneration of \u201cweaver\u201d mice","volume":"165","author":"Panagiotakopoulou","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.3233\/JPD-223183_ref128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.nbd.2008.05.006","article-title":"Fas-associated factor 1 and Parkinson\u2019s disease","volume":"31","author":"Betarbet","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-223183_ref129","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/hmg\/ddt006","article-title":"Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration","volume":"22","author":"Sul","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JPD-223183_ref130","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2147\/DDDT.S198753","article-title":"A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson\u2019s disease, in healthy volunteers","volume":"13","author":"Shin","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.3233\/JPD-223183_ref131","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3389\/fphar.2020.00953","article-title":"Neurorestorative effects of a novel Fas-associated factor 1 inhibitor in the MPTP model: An [18 F]FE-PE2I positron emission tomography analysis study","volume":"11","author":"Park","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.3233\/JPD-223183_ref132","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","article-title":"The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson\u2019s disease","volume":"37","author":"Sharon","year":"2003","journal-title":"Neuron"},{"key":"10.3233\/JPD-223183_ref133","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.molcel.2018.11.028","article-title":"Lipidomic analysis of \u03b1-Synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment","volume":"73","author":"Fanning","year":"2019","journal-title":"Mol Cell"},{"key":"10.3233\/JPD-223183_ref134","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.celrep.2018.11.028","article-title":"Inhibiting stearoyl-CoA desaturase ameliorates \u03b1-synuclein cytotoxicity","volume":"25","author":"Vincent","year":"2018","journal-title":"Cell Rep"},{"key":"10.3233\/JPD-223183_ref135","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2174\/092986710791163939","article-title":"Riluzole, neuroprotection and amyotrophic lateral sclerosis","volume":"17","author":"Cheah","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.3233\/JPD-223183_ref136","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00702-004-0245-5","article-title":"Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (Parkinson variant of multiple system atrophy)","volume":"112","author":"Scherfler","year":"2005","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JPD-223183_ref137","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1468-1331.2006.01452.x","article-title":"Placebo-controlled trial of riluzole in multiple system atrophy","volume":"13","author":"Seppi","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.3233\/JPD-223183_ref138","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS study","volume":"132","author":"Bensimon","year":"2009","journal-title":"Brain"},{"key":"10.3233\/JPD-223183_ref139","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/14734220510008003","article-title":"Modulation of NMDA receptors in the cerebellum. II. Signaling pathways and physiological modulators regulating NMDA receptor function","volume":"4","author":"Sanchez-Perez","year":"2005","journal-title":"Cerebellum"},{"key":"10.3233\/JPD-223183_ref140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/jc.2011-1802","article-title":"Effect of intranasal insulin on cognitive function: A systematic review","volume":"97","author":"Shemesh","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3233\/JPD-223183_ref141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","article-title":"Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?","volume":"118","author":"Bassil","year":"2014","journal-title":"Prog Neurobiol"},{"key":"10.3233\/JPD-223183_ref142","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/mds.23320","article-title":"Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system","volume":"25","author":"Pellecchia","year":"2010","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref143","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.parkreldis.2013.11.005","article-title":"Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson\u2019s disease, multiple system atrophy and progressive supranuclear palsy","volume":"20","author":"Numao","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-223183_ref144","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/brain\/awx044","article-title":"Insulin resistance and exendin-4 treatment for multiple system atrophy","volume":"140","author":"Bassil","year":"2017","journal-title":"Brain"},{"key":"10.3233\/JPD-223183_ref145","doi-asserted-by":"crossref","first-page":"e0214364","DOI":"10.1371\/journal.pone.0214364","article-title":"Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study","volume":"14","author":"Novak","year":"2019","journal-title":"PLoS One"},{"key":"10.3233\/JPD-223183_ref146","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1212115","article-title":"Mutations in COQ2 in familial and sporadic multiple-system atrophy","volume":"369","author":"Collaboration M-SAR","year":"2013","journal-title":"N Engl J Med"},{"key":"10.3233\/JPD-223183_ref147","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.stemcr.2018.09.007","article-title":"Mitochondrial dysregulation and impaired autophagy in iPSC-derived dopaminergic neurons of multiple system atrophy","volume":"11","author":"Monzio Compagnoni","year":"2018","journal-title":"Stem Cell Rep"},{"key":"10.3233\/JPD-223183_ref148","doi-asserted-by":"crossref","first-page":"14215","DOI":"10.1038\/s41598-018-32573-1","article-title":"The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy","volume":"8","author":"Nakamoto","year":"2018","journal-title":"Sci Rep"},{"key":"10.3233\/JPD-223183_ref149","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12311-017-0846-9","article-title":"Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations","volume":"16","author":"Mitsui","year":"2017","journal-title":"Cerebellum"},{"key":"10.3233\/JPD-223183_ref150","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1210\/en.2002-220667","article-title":"Growth hormone action on proliferation and differentiation of cerebral cortical cells from fetal rat","volume":"144","author":"Ajo","year":"2003","journal-title":"Endocrinology"},{"key":"10.3233\/JPD-223183_ref151","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jnr.20719","article-title":"Adult-onset deficiency in growth hormone and insulin-like growth factor-I decreases survival of dentate granule neurons: Insights into the regulation of adult hippocampal neurogenesis","volume":"83","author":"Lichtenwalner","year":"2006","journal-title":"J Neurosci Res"},{"key":"10.3233\/JPD-223183_ref152","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.21501","article-title":"Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study","volume":"22","author":"Holmberg","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref153","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.clpt.6100386","article-title":"Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy","volume":"83","author":"Lee","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JPD-223183_ref154","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.clpt.6100454","article-title":"Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?","volume":"83","author":"Quinn","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JPD-223183_ref155","doi-asserted-by":"crossref","first-page":"e19808","DOI":"10.1371\/journal.pone.0019808","article-title":"Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: Immunomodulation and neuroprotection","volume":"6","author":"Stemberger","year":"2011","journal-title":"PLoS One"},{"key":"10.3233\/JPD-223183_ref156","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","article-title":"A randomized trial of mesenchymal stem cells in multiple system atrophy","volume":"72","author":"Lee","year":"2012","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-223183_ref157","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/WNL.0000000000007720","article-title":"Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy.e77-e","volume":"93","author":"Singer","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JPD-223183_ref158","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3233\/JPD-223183_ref159","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.expneurol.2007.11.022","article-title":"Rasagiline is neuroprotective in a transgenic model of multiple system atrophy","volume":"210","author":"Stefanova","year":"2008","journal-title":"Exp Neurol"},{"key":"10.3233\/JPD-223183_ref160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(14)70288-1","article-title":"Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: A randomised, placebo-controlled trial","volume":"14","author":"Poewe","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-223183_ref161","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.expneurol.2012.01.008","article-title":"Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of \u03b1-synucleinopathy","volume":"234","author":"Ubhi","year":"2012","journal-title":"Exp Neurol"},{"issue":"Suppl 1","key":"10.3233\/JPD-223183_ref162","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/S1353-8020(11)70066-9","article-title":"Fluoxetine protects neurons against microglial activation-mediated neurotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-223183_ref163","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/mds.28569","article-title":"Fluoxetine for the symptomatic treatment of multiple system atrophy: The MSA-FLUO Trial","volume":"36","author":"Rascol","year":"2021","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-223183_ref164","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.parkreldis.2017.12.011","article-title":"Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy?","volume":"48","author":"Coon","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-223183_ref165","doi-asserted-by":"crossref","first-page":"a020479","DOI":"10.1101\/cshperspect.a020479","article-title":"Oligodendrocytes: Myelination and axonal support","volume":"8","author":"Simons","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.3233\/JPD-223183_ref166","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00401-016-1572-y","article-title":"\u03b1-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy","volume":"132","author":"Ettle","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-223183_ref167","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/glia.22437","article-title":"Toll-like receptor 4 is required for \u03b1-synuclein dependent activation of microglia and astroglia","volume":"61","author":"Fellner","year":"2013","journal-title":"Glia"},{"key":"10.3233\/JPD-223183_ref168","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.ajpath.2011.04.013","article-title":"Toll-like receptor 4 promotes \u03b1-synuclein clearance and survival of nigral dopaminergic neurons","volume":"179","author":"Stefanova","year":"2011","journal-title":"Am J Pathol"},{"key":"10.3233\/JPD-223183_ref169","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13024-017-0195-7","article-title":"Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal \u03b1-synucleinopathy","volume":"12","author":"Venezia","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JPD-223183_ref170","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/hmg\/ddl243","article-title":"Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity","volume":"15","author":"Kontopoulos","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JPD-223183_ref171","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s13311-016-0447-1","article-title":"Neuroprotection by epigenetic modulation in a transgenic model of multiple system atrophy","volume":"13","author":"Sturm","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JPD-223183_ref172","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2015.05.004","article-title":"Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative","volume":"80","author":"Laurens","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-223183_ref174","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nan.12304","article-title":"Review: Multiple system atrophy: Emerging targets for interventional therapies","volume":"42","author":"Stefanova","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JPD-223183_ref175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10286-014-0266-6","article-title":"Animal models of multiple system atrophy","volume":"25","author":"Stefanova","year":"2015","journal-title":"Clin Auton Res"},{"key":"10.3233\/JPD-223183_ref176","doi-asserted-by":"crossref","first-page":"105184","DOI":"10.1016\/j.nbd.2020.105184","article-title":"Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease","volume":"148","author":"Marmion","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-223183_ref177","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/7854_2013_269","article-title":"Models of multiple system atrophy","volume":"22","author":"Fellner","year":"2015","journal-title":"Curr Top Behav Neurosci"},{"key":"10.3233\/JPD-223183_ref178","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00401-004-0935-y","article-title":"The role of alpha-synuclein in the pathogenesis of multiple system atrophy","volume":"109","author":"Wenning","year":"2005","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-223183_ref179","unstructured":"Levin J , Maass S , Schuberth M , Giese A , Wolfgang O , Werner P , Trenkwalder C , Gregor W , Mansmann U , Suedmeyer M , Eggert K , Mollenhauer B , Lipp A , Loehle M , Classen J , Muenchau A , Kassubeck J , Ebersbach G , Berg D , Egert S , Eberhardt C , Paul F , Boetzel K , Ertl-Wagner B , Huppertz H , Ricard I , Hoeglinger G (2018) PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG sup-plementation as anti-aggregation-approach. Mov Disord 33 (Suppl 2), https:\/\/www.mdsabstracts.org\/abstract\/promesa-a-randomised-double-blind-placebo-controlled-trial-to-evaluate-the-progression-rate-of-msa-under-egcg-supplementation-as-anti-aggregation-approach\/"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-223183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:51:41Z","timestamp":1777611101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-223183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":171,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.3233\/jpd-223183","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}